Our Mission

Our Mission is to improve the lives of patients suffering from difficult to treat cancers, with a focus on pancreatic cancer through novel therapies that prime and boost their immune response and improve the performance of their cancer treatment, enabling them to live longer.

About Us

Immodulon is a private, late-stage clinical company developing IMM-101, a novel broad spectrum immunomodulator. IMM-101 induces a broad immune response, modulating the innate and adaptive immune systems with a potential to complement existing therapies, including targeted immunotherapies and cytotoxics. IMM-101 has the potential to work in difficult-to-treat tumours, including those that have been considered immunologically ‘cold’.

Immodulon has generated promising phase II data with IMM-101 in first line patients with advanced pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine.

Latest from Immodulon